{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.63","upperLimit":"4.21","value":"2.04"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"PFS is the time from start of study treatment to first documentation of progression, or to death due to any cause, whichever comes first","dispersionType":"95% Confidence Interval","groups":[{"description":"Part 2 / treatment group A (TGA): dose titration was to determine the feasibility of intraparticipant dose titration using Protocol-defined criteria. Treatment Group A included any advanced solid tumor or lymphoma.","id":"OG000","title":"Part 2 / Treatment Group A: 20 MG BID INCB054329"},{"description":"Part 2 / treatment group C (TGC): dose titration was to determine the feasibility of intraparticipant dose titration using Protocol-defined criteria. Treatment Group C included multiple myeloma.","id":"OG001","title":"Part 2 / Treatment Group C: 20 mg BID INCB054329"}],"paramType":"MEDIAN","populationDescription":"As a result of early termination of the study, only participants in Part 2 of the study were evaluated; Treatment Group C was not evaluated due to early termination from the study.","reportingStatus":"POSTED","timeFrame":"Baseline through end of study, up to 6 months","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}